The Effect of Corticosteroid Medication on Quantitative MR Parameters of the Brain

References

1. ↵
   Sibbitt WL, Sibbitt RR, Brooks WM. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999;42:2026–2038

   CrossRefPubMedWeb of Science
2. ↵
   Huizinga TW, Steens SC, van Buchem MA. Imaging modalities in central nervous system systemic lupus erythematosus. Curr Opin Rheumatol 2001;13:383–388

   CrossRefPubMedWeb of Science
3. ↵
   Tofts PS, Steens SC, van Buchem MA. MT: magnetization transfer. In: Tofts PS, ed. Quantitative MRI of the brain: measuring changes caused by disease. 1st ed. Chichester: Wiley;2003 :257–298
4. ↵
   Wheeler-Kingshott CA, Barker GJ, Steens SC, et al. D: the diffusion of water. In: Tofts PS, ed. Quantitative MRI of the brain: measuring changes caused by disease. 1st ed. Chichester: Wiley;2003 :203–256
5. ↵
   Tofts PS, Waldman AD. Spectroscopy: 1H metabolite concentrations. In: Tofts PS, ed. Quantitative MRI of the brain: measuring changes caused by disease. 1st ed. Chichester: Wiley;2003 :299–339
6. ↵
   Bosma GP, Rood MJ, Zwinderman AH, et al. Evidence of central nervous system damage in patients with neuropsychiatric systemic lupus erythematosus, demonstrated by magnetization transfer imaging. Arthritis Rheum 2000;43:48–54

   CrossRefPubMedWeb of Science
7. ↵
   Bosma GP, Rood MJ, Huizinga TW, et al. Detection of cerebral involvement in patients with active neuropsychiatric systemic lupus erythematosus by the use of volumetric magnetization transfer imaging. Arthritis Rheum 2000;43:2428–2436

   CrossRefPubMedWeb of Science
8. Bosma GP, Huizinga TW, Mooijaart SP, van Buchem MA. Abnormal brain diffusivity in patients with neuropsychiatric systemic lupus erythematosus. AJNR Am J Neuroradiol 2003;24:850–854

   Abstract/FREE Full Text
9. ↵
   Sibbitt WL, Haseler LJ, Griffey RH, et al. Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy. AJNR Am J Neuroradiol 1994;15:923–928

   Abstract/FREE Full Text
10. Brooks WM, Sabet A, Sibbitt WL, et al. Neurochemistry of brain lesions determined by spectroscopic imaging in systemic lupus erythematosus. J Rheumatol 1997;24:2323–2329

    PubMedWeb of Science
11. ↵
    Sibbitt WL, Haseler LJ, Griffey RR, et al. Neurometabolism of active neuropsychiatric lupus determined with proton MR spectroscopy. AJNR Am J Neuroradiol 1997;18:1271–1277

    Abstract
12. ↵
    Bosma GP, Steens SC, Petropoulos H, et al. Multisequence magnetic resonance imaging study of neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2004;50:3195–3202

    CrossRefPubMedWeb of Science
13. ↵
    Steens SC, Admiraal-Behloul F, Bosma GP, et al. Selective gray matter damage in neuropsychiatric lupus. Arthritis Rheum 2004;50:2877–2881

    CrossRefPubMedWeb of Science
14. ↵
    Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003;32:370–377

    CrossRefPubMedWeb of Science
15. ↵
    Nadeau SE. Neurologic manifestations of connective tissue disease. Neurol Clin 2002;20:151–178, vi

    CrossRefPubMedWeb of Science
16. ↵
    Lundberg IE, Grundtman C, Larsson E, Klareskog L. Corticosteroids: from an idea to clinical use. Best Pract Res Clin Rheumatol 2004;18:7–19

    CrossRefPubMed
17. ↵
    Keenan PA, Jacobson MW, Soleymani RM, et al. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology 1996;47:1396–1402

    Abstract/FREE Full Text
18. ↵
    Zanardi VA, Magna LA, Costallat LT. Cerebral atrophy related to corticotherapy in systemic lupus erythematosus (SLE). Clin Rheumatol 2001;20:245–250

    CrossRefPubMedWeb of Science
19. ↵
    Rao AB, Richert N, Howard T, et al. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology 2002;59:688–694

    Abstract/FREE Full Text
20. ↵
    Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–324

    CrossRefPubMedWeb of Science
21. ↵
    Naressi A, Couturier C, Castang I, et al. Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med 2001;31:269–286

    CrossRefPubMedWeb of Science
22. ↵
    Woods RP, Grafton ST, Holmes CJ, et al. Automated image registration. I. General methods and intrasubject, intramodality validation. J Comput Assist Tomogr 1998;22:139–152

    CrossRefPubMedWeb of Science
23. ↵
    Woods RP, Grafton ST, Watson JD, et al. Automated image registration. II. Intersubject validation of linear and nonlinear models. J Comput Assist Tomogr 1998;22:153–165

    CrossRefPubMedWeb of Science
24. ↵
    Steens SC, Admiraal-Behloul F, Schaap JA, et al. Reproducibility of brain ADC histograms. Eur Radiol 2004;14:425–430

    CrossRefPubMed
25. ↵
    van den Boogaart A, van Ormondt D, Pijnappel WWF, de Beer R, Ala Korpela M. Removal of the water resonance from 1H magnetic resonance spectra. In: Mathematics in signal processing, 3rd ed. Oxford: Clarendon Press;1994 :175–195
26. ↵
    Vanhamme L, van den BA, van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997;129:35–43

    CrossRefPubMedWeb of Science
27. ↵
    Funauchi M, Ohno M, Nozaki Y, et al. Intrathecal corticosteroids for systemic lupus erythematosus with central nervous system involvement. J Rheumatol 2003;30:207–208

    FREE Full Text
28. ↵
    Hoogervorst EL, Polman CH, Barkhof F. Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Mult Scler 2002;8:415–419

    Abstract/FREE Full Text
29. ↵
    Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239–1247

    Abstract/FREE Full Text
30. ↵
    Bilaniuk LT, Patel S, Zimmerman RA. Computed tomography of systemic lupus erythematosus. Radiology 1977;124:119–121

    CrossRefPubMedWeb of Science
31. ↵
    Ostrov SG, Quencer RM, Gaylis NB, Altman RD. Cerebral atrophy in systemic lupus erythematosus: steroid- or disease-induced phenomenon? AJNR Am J Neuroradiol 1982;3:21–23

    Abstract/FREE Full Text
32. ↵
    Friedman SD, Stidley CA, Brooks WM, et al. Brain injury and neurometabolic abnormalities in systemic lupus erythematosus. Radiology 1998;209:79–84

    PubMedWeb of Science
33. ↵
    Khiat A, Yared Z, Bard C, Lacroix A, Boulanger Y. Long-term brain metabolic alterations in exogenous Cushing’s syndrome as monitored by proton magnetic resonance spectroscopy. Brain Res 2001;911:134–140

    CrossRefPubMed
34. ↵
    Brown ES, Woolston J, Frol A, et al. Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biol Psychiatry 2004;55:538–545

    CrossRefPubMedWeb of Science
35. ↵
    Rollins N, Winick N, Bash R, Booth T. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR Am J Neuroradiol 2004;25:1688–1695

    Abstract/FREE Full Text
36. ↵
    Ebner F, Ranner G, Slavc I, et al. MR findings in methotrexate-induced CNS abnormalities. AJR Am J Roentgenol 1989;153:1283–1288

    PubMedWeb of Science